Targeting p53-null neuroblastomas through RLIP76

Cancer Prevention Research

Volumn 4, Issue 6, 2011, Pages 879-889

  Singhal, Jyotsana ^a   Yadav, Sushma ^a   Nagaprashantha, Lokesh Dalasanur ^a   Vatsyayan, Rit ^a   Singhal, Sharad S ^a   Awasthi, Sanjay ^a,b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CARRIER PROTEIN; CISPLATIN; DOXORUBICIN; MUTANT PROTEIN; PROTEIN P53; RLIP76 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CHILD; COMPLEX FORMATION; CONJUGATE; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING; MALE; MOUSE; MULTIDRUG RESISTANCE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEIN TRANSPORT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CHILD; CISPLATIN; CROSS-LINKING REAGENTS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; GTPASE-ACTIVATING PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MALE; MICE; MICE, NUDE; NEUROBLASTOMA; OLIGONUCLEOTIDES, ANTISENSE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957862487     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0025     Document Type: Article

References (50)

1. Berthold F, Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 2000;59: 1261-77. (Pubitemid 30410144)
2. Jacob ES, Varghese RG, Toi PC, Bhaskaran R, Rai R. Congenital neuroblastoma with liver metastasis presenting with Hashimoto Pritzker disease. Ind J Pathol Microbiol 2009;52:374-6.
3. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;21:181-9. (Pubitemid 30306028)
4. Smith SJ, Diehl N, Leavitt JA, Mohney BG. Incidence of pediatric Horner syndrome and the risk of neuroblastoma: a population-based study. Arch Ophthalmol 2010;128:324-29.
5. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64:6883-91. (Pubitemid 39330995)
6. Hawkes WC, Alkan Z. Regulation of redox signaling by selenoproteins. Biol Trace Elem. Res 2010;134:235-51.
7. Children's Oncology Group (CCG 09709),Khan J, Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, et al. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006;24:3423-30.
8. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003;9:2032-39. (Pubitemid 36687622)
9. Fong A, Park JR. High-risk neuroblastoma: A therapy in evolution. Pediatr Hematol Oncol 2009;26:539-48.
10. Kubota M, Okuyama N, Hirayama Y, Asami K, Ogawa A, Watanabe A. Mortality and morbidity of patients with neuroblastoma who survived for more than 10 years after treatment-Niigata Tumor Board Study. J Pediatr Surg 2010;45:673-77.
11. Modak S, Cheung NK. Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 2010;36:307-17.
12. Seeger RC, Reynolds CP. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am 1991;38:393-424.
13. Manhani R, Cristofani LM, Odone Filho V, Bendit I. Concomitant p53 mutation and MYCN amplification in neuroblastoma. Med Pediatr Oncol 1997;29:206-7. (Pubitemid 27291142)
14. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001;61:6185-93. (Pubitemid 32768583)
15. Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 1998;16:2345-9. (Pubitemid 28226881)
16. Lee JM, Bernstein A. P53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci U S A 1993;90:5742-6. (Pubitemid 23176238)
17. Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. Discov Med 2010;45:145-52.
18. Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP. P53 mutations and loss of P53 function confer multidrug resistance in neuroblastoma. Med Pediatr Oncol 2000;35:563-8.
19. Awasthi S, Singhal SS, Sharma R, Zimniak P, Awasthi YC. Transport of glutathione-conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): a novel link between G-protein and tyrosine kinase signaling and drug resistance. Int J cancer 2003;106:635-46. (Pubitemid 36993386)
20. Vatsyayan R, Lelsani P, Awasthi S, Singhal SS. RLIP76: a versatile transporter and an emerging target for cancer therapy. Biochem Pharmacol 2010;79:1699-705.
21. Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, et al. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 2008;10: 1268-74.
22. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 2004;24:6728-41.
23. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998;58:5396-405. (Pubitemid 28551122)
24. Awasthi S, Cheng J, Singhal SS, Saini MK, Pandya U, Pikula S, et al. Novel function of human RLIP76: ATP-dependent transport of glutathione- conjugates and doxorubicin. Biochemistry 2000;39:9327-34. (Pubitemid 30626323)
25. Sharma R, Singhal SS, Cheng J, Yang Y, Sharma A, Zimniak P, et al. RLIP76 is the major ATP-dependent transporter of glutathione-conjugates and doxorubicin in human erythrocytes. Arch Biochem Biophys 2001;391:171-9. (Pubitemid 32662258)
26. Aumais JP, Lee HS, Lin R, White JH. Selective interaction of hsp90 with an estrogen receptor ligand-binding domain containing a point mutation. J Biol Chem 1997;272:12229-35. (Pubitemid 27202809)
27. Awasthi S, Singhal SS, Pikula S, Piper JT, Srivastava SK, Torman RT, et al. ATP-dependent human erythrocyte glutathione-conjugate transporter. II. Functional reconstitution of transport activity. Biochemistry 1998;37:5239-48.
28. Yadav S, Singhal SS, Singhal J, Wickramarachchi D, Knutson E, Albrecht TB, et al. Identification of membrane-anchoring domains of RLIP76 using deletion mutant analyses. Biochemistry 2004;43: 16243-53. (Pubitemid 40041037)
29. Singhal SS, Yadav S, Singhal J, Drake K, Awasthi YC, Awasthi S. The role of PKCa and RLIP76 in transport-mediated doxorubicin-resistance in lung cancer. FEBS Lett 2005;579:4635-41. (Pubitemid 41218639)
30. Bensaad K, Vousden KH. Savior and slayer: the two faces of p53. Nat Med 2005;11:1278-9. (Pubitemid 41752901)
31. Dwivedi S, Sharma A, Patrick B, Sharma R, Awasthi YC. Role of 4-hydroxynonenal and its metabolites in signaling. Redox Rep 2007; 12:4-10. (Pubitemid 46210346)
32. Lee YS, Wan J, Kim BJ, Bae MA, Song BJ. Ubiquitin-dependent degradation of p53 protein despite phosphorylation at its N terminus by acetaminophen. J Pharmacol Exp Ther 2006;317:202-8.
33. Bardag-Gorce F, French BA, Nan L, Song H, Nguyen SK, Yong H, et al. CYP2E1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (mallory body-like) formation. Exp Mol Pathol 2006;81:191-201. (Pubitemid 44665867)
34. Tonini GP, Parodi MT, Di Martino D, Varesio L. Expression of protein kinase C-alpha (PKC-alpha) and MYCN mRNAs in human neuroblastoma cells and modulation during morphological differentiation induced by retinoic acid. FEBS Lett 1991;280:221-4.
35. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the children's oncology group. J Clin Oncol 2005;23:6459-65. (Pubitemid 46190236)
36. Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 1997;79:2028-35. (Pubitemid 27200389)
37. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;21:181-9. (Pubitemid 30306028)
38. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-95. (Pubitemid 27234938)
39. Fulda S, Lutz W, Schwab M, Debatin KM. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999;18: 1479-86. (Pubitemid 29103635)
40. Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 1998;16:3286-94. (Pubitemid 28481623)
41. Carr J, Bell E, Pearson AD, Kees UR, Beris H, Lunec J, et al. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 2006;66: 2138-45.
42. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci 2005;102:731-6. (Pubitemid 40282734)
43. Cheng JZ, Sharma R, Yang Y, Singhal SS, Sharma A, Saini MK, et al. Accelerated metabolism and exclusion of 4-hydroxynonenal through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative stress. J Biol Chem 2001;276:41213-23.
44. Rosse C, L'Hoste S, Offner N, Picard A, Camonis J. RLIP, an effector of the ral GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis. J Biol Chem 2003;278:30597-604. (Pubitemid 36994564)
45. Jullien-Flores V, Dorseuil O, Romero F, Letourneur F, Saragosti S, Berger R, et al. Bridging ral GTPase to rho pathways. RLIP76, a ral effector with CDC42/Rac GTPase-activating protein activity. J Biol Chem 1995;270:22473-7.
46. Singhal SS, Yadav S, Vatsyayan R, Chaudhary P, Borvak J, Singhal J, et al. Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis. Cancer Lett 2009;283:152-8.
47. Singhal SS, Yadav S, Drake K, Singhal J, Awasthi S. Hsf-1 and POB1 induce drug sensitivity and apoptosis by inhibiting Ralbp1.J Biol Chem 2008;283:19714-29.
48. Singhal SS, Awasthi YC, Awasthi S. Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res 2006;66:2354-60.
49. Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor PJ, Awasthi YC, et al. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (ral-binding protein 1). Cancer Res 2007;67:4382-9. (Pubitemid 46815087)
50. Singhal SS, Singhal J, Yadav S, Sahu M, Awasthi YC, Awasthi S. RLIP76: a target for kidney cancer therapy. Cancer Res 2009;69: 4244-51.